Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Thoracic Radiotherapy in ED-SCLC
NCT04472949Phase 2Active, not recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2021
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04472949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472949.